HER-2 Protein Overexpression, HER-2 Gene Amplification
Conditions
Keywords
HER-2 Protein Overexpression, HER-2 Gene Amplification, HER2 targeted-treatment, Trastuzumab biosimilar, samfenet
Brief summary
HER2 signaling pathway abnormalities or HER2 overexpression can be seen in various types of solid tumors apart from breast cancer or hepatic cancer. In this regardHER2 targeting therapy has been proven to be effective in colorectal cancer, gallbladder cancer, and salivary gland tumors. Although HER2 targeted-treatment Trastuzumab biosimilar is clinically being used after gaining official permission recently, clinical data for this use is still lacking, especially regarding experiences of combination with various cytotoxic chemotherapy agents. Notably, techniques to separate and extract a small sized ciculating tumor DNA (ctDNA) in patient's blood originated from a tumor is being developed and improved along with introduction of Next-generation sequencing (NGS) technique enabling a comprehensive genetic testing. The aim of this study is to evaluate the efficacy and safety of Trastuzumab biosimiler and to investigate the association between ctDNA and clinical outcomes such as disease response, progression-free survival, and overall survival.
Detailed description
Samfenet is a biosimilar of trastuzumab and received marketing approval based on the results of efficacy equivalence to trastuzumab. This study is a phase 2 study to investigate the efficacy of Samfenet in combination with cytotoxic agents in patients with HER2-positive solid tumors. A total of 42 patients will be enrolled. Treatment will be continues until disease progression, unacceptable toxicity or patient withdrawal. Tumor evaluation will be performed at every 8 weeks during treatment, and then at every 12 weeks thereafter end of study.
Interventions
1st cycle 8 mg/kg by IV infusion over 90 mins, from 2nd cycle 6mg/kg by IV infusion over 30 mins. every 3weeks.
DRUGGemcitabine Hydrochloride
1000 mg/m2 by IV infusion over 30 minutes on Day 1, Day 8. every 3weeks.
DRUGIrinotecan Hydrochloride
100 mg/m2 by IV infusion over 90 minutes on Day 1, Day 8. every 3weeks.
Sponsors
Asan Medical Center
Jin-Hee Ahn
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
19 Years to 79 Years
Healthy volunteers
No
Inclusion criteria
* Histologically or cytologically confirmed HER2 -overexpression (HER2 overexpression defined as 3+ positive by immunohistochemistry, positive by fluorescence in situ hybridization (FISH), or confirmation of HER2 amplification). However hepatic cancer and breast cancer are exclude as HER2 targeted treatment is already a standard treatment for these tumor types. * Patients who have progressed after at least one standard treatment or unable to continue standard treatment due to adverse events. * Patients confirmed as metastatic or unresectable cancer by imaging test * At least one measurable lesion that can be accurately assessed by imaging according to RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2 at trial entry * Adequate organ function (bone marrow, liver, kidney function) A. ANC ≥ 1000/mL B.Platelets ≥ 75,000/uL C.Hemoglobin \>8.0 g/dL D.Total bilirubin ≤ 2.0x ULN E.AST and ALT \< 5.0 x ULN F.Alkaline phosphatase \<2.5x ULN GCreatinine ≤ 2.0x ULN or CCr \>30 ml/min * Estimated life expectancy of more than 3 months * Left ventricular ejection fraction of at least ≥ 50% at trial entry * Age ≥19 years who have signed an informed consent approved by Institutional Review Board of Organization
Exclusion criteria
* Either woman of pregnancy or breast-feeding woman who is positive for hCG * Symptomatic or unstable metastases to central nervous system (exceptions : properly treated brain metastasis with no evidence of progression on CT or MRI scan compared with prior examination and without requirement for steroid therapy for relief of symptom. Treatment of an anticonvulsant of stable dose for more than 4 months is permitted taken. * Evidence of viral, bacterial, or fungal infection including active hepatitis C and D or HIV infection. * Underwent major surgery of have not fully recovered from certain procedures within 4 months prior to taking the investigational product * History of malignant disease within 3 years prior to taking the investigational product (exceptions: treated carcinoma in situ of cervix, differentiated thyroid cancer without lymph node metastasis, and skin cancer other than melanoma). * Interval of QTc \> 480 msec (in terms of average measurement of EKG 3 times), oneself or family known to be long or short QT, brugada syndrome or other known QTc prolongation history or Torsade de Pointes. * Following symptoms or disease within 6 months prior to taking the investigational product: myocardiac infarction, NCI CTCAE v 5.0 Grade ≤2 severe/unstable angina, continuous arrhythmia, atrial fibrillation, bypass surgery of coronary or peripheral arteries, symptomatic heart failure, cerebrovascular events including transient ischemic attack, or symptomatic pulmonary embolism. * History of symptomatic interstitial lung disease * Hypersensitivity reaction to Trastuzumab, Gemcitabine, Irinotecan or components of these agents * Patients with diarrhea, intestinal paralysis, intestinal obstruction, massive ascites, or pleural effusion * Other psychiatric problems, suicidal attempt, abnormal test results that can affect the administration of the investigational product or participation of clinical trial or that can impact the results of the clinical trial, and any other reason that investigator acknowledge as unsuitable factor for participating the clinical trial.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| objective response rate | 8 weeks | Best response according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progression-free survival (PFS) | 3 years | PFS is defined as the time from the first dose of trial treatment to the date of disease progression or death due to any cause, whichever occurs first. |
| overall survival (OS) | 3 years | OS is defined as the time from the first dose of trial treatment to the death of all causes or the last follow-up. |
| Safety profile: NCI-CTCAE | 3 years | Adverse events graded by National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 |
Outcome results
None listed